Ironwood Pharmaceuticals (IRWD) said Monday that a confirmatory phase 3 trial is needed to seek approval of apraglutide for patients with short bowel syndrome based on a recent discussion with the US Food and Drug Administration.
Ironwood also said it has retained Goldman Sachs (GS) to explore strategic alternatives for the company to maximize shareholder value.
Shares of Ironwood sank 31% following an increase in intraday trading volume to over 9.9 million from a daily average of about 3.4 million.
MicroCloud Hologram (HOLO) said its board decided April 21 as the effective date for its 1-for-40 reverse share split.
Shares slumped 21% as intraday trading volume rose to over 39.3 million versus a daily average of about 31.1 million.
Safe & Green (SGBX) said Monday it priced a private placement of roughly 20.4 million units at $0.392 apiece to raise almost $8 million in gross proceeds. The company plans to use the net proceeds for working capital, general corporate purposes and equipment for expansion.
Shares retreated 13% as intraday trading volume climbed to more than 860,000 from a daily average of roughly 4.9 million.
Price: 0.65, Change: -0.29, Percent Change: -30.90
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.